Brentuximab vedotin: axonal microtubule's Apollyon.

Item

http://www.wikidata.org/entity/Q43067218

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Brentuximab vedotin: axonal microtubule's Apollyon.

@en

Brentuximab vedotin: axonal microtubule's Apollyon.

@nl

type

Item

label

Brentuximab vedotin: axonal microtubule's Apollyon.

@en

Brentuximab vedotin: axonal microtubule's Apollyon.

@nl

prefLabel

Brentuximab vedotin: axonal microtubule's Apollyon.

@en

Brentuximab vedotin: axonal microtubule's Apollyon.

@nl

P1476

Brentuximab vedotin: axonal microtubule's Apollyon.

@en

P2093

F Benedetti

http://www.w3.org/2001/XMLSchema#string

G Tridente

http://www.w3.org/2001/XMLSchema#string

M Sorio

http://www.w3.org/2001/XMLSchema#string

S Ferrari

http://www.w3.org/2001/XMLSchema#string

S Mariotto

http://www.w3.org/2001/XMLSchema#string

S Monaco

http://www.w3.org/2001/XMLSchema#string

T Cavallaro

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Peripheral neuropathy induced by microtubule-stabilizing agents.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Chemotherapy-induced peripheral neuropathies in hematological malignancies.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

P2888

bcj.2015.72

P304

e343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2015.72

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Gajofatto

P577

2015-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281553534

http://www.w3.org/2001/XMLSchema#string

P6179

1037720992

http://www.w3.org/2001/XMLSchema#string

P698

26314985

http://www.w3.org/2001/XMLSchema#string

P932

4558596

http://www.w3.org/2001/XMLSchema#string